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Accumulating evidence indicates  that interferons  may have a regulatory role  in 
several  immune functions.  Interferons  suppress  proliferation  of  lymphocytes  in  response 
to mitogens and antigens (1),  inhibit  antibody formation  (2-4),  and enhance the 
generation of specific  cytotoxic  effector  cells  (5, 6). The phagocytic activity  of mouse 
macrophages (7,  8)  and the suppression  of  tumor cell  growth mediated  by mouse spleen 
cells (9) have been shown to be enhanced by interferon  in in vivo and in vitro 
experiments. 
Lymphocytes from human peripheral blood obtained from any normal donor are 
spontaneously cytotoxic  in vitro  for target cell  lines  (10-14).  The cytotoxic  activity  is 
mediated  by  natural  killer  cells  that  have  been  identified  as  Fc-receptor  positive,  surface 
irnmunoglobulin negative  lymphocytes (11,  12).  Only a small proportion  of  natural  killer 
cells  form  rosettes  with  sheep  erythrocytes  (11,  12,  15,  16)  when very  sensitive  techniques 
employing erythrocytes  treated  with a sulphydryl reagent (17)  or  with  enzymes (18)  are 
used.  The natural killer  cells  in  human peripheral  blood  cannot  be  separated from cells 
involved  in  antibody-dependent cell-mediated  lysis  which suggests  that  the  two  types  of 
cytotoxicity  may be mediated by the same cell  population (12-14,  19). 
We have shown that  cells  from certain  tumor-derived or virus-transformed 
lines effectively induce interferon production when  cultured together with 
human  or mouse lymphocytes (20).  For the present study we investigated the 
effects  that the interferon produced in such mixed cultures exerts on the two 
cell  populations: interferon enhances the spontaneous cytotoxic activity of  the 
lymphocytes and has an antagonistic inhibitory activity on the susceptibility 
of  the target cell  lines to cell-mediated lysis. 
Materials and Methods 
Reagents.  Cycloheximide  and 2-aminoethylisothio-uronium  bromide  hydrobromide (AET)  ~ 
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were obtained from Sigma Chemical Co. (St.  Louis,  Mo.);  actinomycin D from Calbiochem (San 
Diego, Calif.);  fluorescein  isothiocianate-conjugated  goat  F(ab')s  fragment anti-human IgG  F(ab')s 
fragment from Cappel Laboratories, Inc. (Cochranville,  Pa.);  and sheep erythrocytes from Flow 
Laboratories, Inc. (Rockville,  MD). 
Cell  Lines  and Viruses.  The origins  of  most  of  the  cell  lines  used  in  this  study  are  summarized 
in Table I (20).  Adherent cells  were subculturod in Eagle's minimum essential  medium supple- 
mented with 10% fetal  bovine serum (FBS) (Flow Laboratories).  The human lymphoid line  EB-P8 
was obtained by  transforming peripheral blood lymphocytes from a multiple sclerosis  patient  with 
Epstein-Barr virus. It was subcultured  in RPMI  1640 medium  supplemented with 10% FBS, 
penicillin (100  international U/ml), and streptomycin  (100 /~g/ml) (RPMI-FBS,  Flow Labora- 
tories). 
Newcastle disease virus (NDV) was obtained from T. J. Wiktor (Wistar Institute)  [allantoic 
fluid, 3.3 ×  10' plaque-forming units (PFU)/ml on L929 mouse cells].  The Indiana strain of 
vesicular  stomatitis  virus (VSV) was originally  obtained from T. J. Wiktor and grown in tissue 
culture on human rhabdomyosarcoma-derived  cells  (RDMC)  (3 x  108 PFU/ml on L-F2 mouse 
cells).  Vaccinia virus (Lister  strain),  provided by M. Herlyn (Wistar Institute)  was originally 
obtained from Wyeth Laboratories (Radnor, Pa.)  and grown in W138 cells  [106  tissue  culture in- 
fectious  doses 50% (TCID~)/ml on W138 cells].  The Hong Kong/107/68 (H3N2) strain  of  influenza 
A virus was obtained from W. Gerhard (Wistar Institute)  (allantoic  fluid,  850 hemagglutination 
units [HAU]/ml). 
Lymphocyte  Separation  and  Culture.  Mononuclear  cells  were  obtained  from  heparinized 
human peripheral blood by separation on a Ficoll-Hypaque gradient. The methods for separating 
subpopulatious of human lymphocytes have been previously described (20).  Briefly, lymphocytes 
were depleted of monocytes and of most B cells by incubation on a  nylon column, according to a 
modification (20) of the method of Julius et al.  (21).  T-cell-enriched and depleted fractions were 
obtained by separating lymphocytes  rosetting with  AET-treated  sheep erythrocytes  (22)  from 
nonrosetting  lymphocytes  on  a  FicoU-Hypaque  gradient.  Erythrocytes  were  eliminated  from 
rosetted cells by distilled water lysis.  For culturing lymphocyte preparations in the presence or 
absence of interferon, cell suspensions at 5 x  10  ~ cells/ml in RPMI-FBS were incubated at 37°C in 
a  humidified 5% COs atmosphere, in standing tissue culture flasks (3013,  2-3 ml/flask; 3024,  10 
ml/flask; BioQuest, BBL, & Falcon Products, Becton, Dickinson & Co., Cockeysville, Md.). At the 
end of the incubation, cells were washed three times in phosphate-buffered saline (PBS), pH 7.2, 
and viable cells were counted with an erythrosin B solution (23) and resuspnded in RPMI-FBS. 
NDV Induction of Lymphocyte Interferon.  NDV at a  multiplicity of infection (MOI) of 20 was 
added to a suspension (10  ~ cells/ml in RPMI-FBS) of human lymphocytes. After an 16 h incubation 
(37°C)  the cells were eliminated by centrifugation (30 min, 30,000 g); the superuatant was then 
brought to pH 2.0 with HC1,  1 N, incubated for 5 days at 4°C,  neutralized to pH 7.0 with NaOH 1 
N, passed through a sterile filter (porosity 0.45/~m, Nalge Co., Nalgene Labware Div., Rochester, 
N.Y.) and stored at -80°C. 
Interferon  Production  in  Mixed  Tumor-Lymphocyte  Cultures.  Human  lymphocytes  were 
depleted of adherent cells by two passages (1 h each at 37°C) on glass Petri dishes and resuspended 
at 10  T  cells/ml in RPMI-FBS. 8-10 ml of the cell suspension was added to confluent monolayers of 
RDMC  cells  in  75  cm  s  tissue  culture  flasks  (3024,  BioQuest,  BBL,  &  Falcon  Products)  and 
incubated 18 h at 37~C. The supernates were centrifuged at 30,000 g  for 30 min, filtered through a 
sterile 0.45 ~m filter, and stored at -80°C. 
Interferon  Assay.  Anti-viral  titers  of  human  interferon  preparations  were  measured  as 
previously described (20) by inhibition of the cytopathic effect of VSV on a  monolayer of human 
fetal skin fibroblasts (FS1).  Anti-viral units are expressed as the reciprocal of highest dilution 
inhibiting 50% of the cytopathic effect and are equivalent to approximately 1 reference U of the 
NIH Human  Reference Interferon  G-023-901-527. 
Cell-Mediated Cytotoxicity on Adherent Target Cells.  Trypsinized target cells were seeded into 
the wells of fiat bottom microtiter plates (3040, BioQuest, BBL, & Falcon Products) at a dose of 2 
x  10' cells/well; 2/zCi of NasS~CrO, (New England Nuclear Corp., Boston, Mass.) were added to 
each well,  and the plates were incubated overnight at 37°C.  The plates were then washed three 
times and 0.1 ml of RPMI-FBS or interferon diluted in medium was added in each well. Effector 
cell dilutions of 0.1 ml were added, and the plates were incubated at 37°C in a humidified 5% COs 
atmosphere for the indicated times. After centrifugation, 0.1 ml of the supernatant A  was then 
collected from each well and 0.1 ml of 1% Triton X-100 added. The plates were further incubated 1316  INTERFERON  AND  HUMAN  NATURAL  KILLER  CELL  ACTIVITY 
for at least 4 h at 37°C and 0.1 ml of supernatant B was again collected from each well. Samples A 
and B were counted for 5~Cr activity; percent ~Cr release (E) was calculated as: 
A 
E  × 100. 
B +  A/2 
All experimental and control values were the mean of at least three replicates. Where S is the 
percent 5~Cr release from target cells in the presence of medium alone, the specific percent 5~Cr 
release (R) was computed as: 
E  -  S  ×  100 
R 
100  -  s 
Antibody-Dependent  Cell-Mediated Cytotoxicity.  The method has been previously described in 
detail (13,  24,  25). The established lymphoblastoid B-cell line EB-P8, with phenotype HLA-A3, 
B5, 7 was used as target.  [~Cr]labeled  target  cells  were sensitized  with a mixture of  anti-HLA 
sera BsSh (anti-B7,  diluted 1/20)  and ToBU 1.64  (anti-B5,  12, purified  IgG, 0.1 mg/ml) both of 
which were obtained from the Instituto  di Genetica  Medica, University of  Torino (Italy). 
Computation of  Lytic Units.  Dose-response curves of  specific  cytetoxicity  (both  for antibody- 
dependent  and direct  cell-mediated  cytotoxicity)  were determined  by plotting  specific  51Cr  release 
versus the number of  effector  lymphocytes. The number of  lymphocytes necessary to lyse  50% of 
the target  cells  in  the incubation time was  referred  to  as I  lytic  U. Determination  of  the 50% lytic 
units  was  done  graphically  or  computed on  the  basis  of  a modification  (24)  of  the van  Krogh equa- 
tion. 
Mouse Anti-Human Cytotoxic T Cells.  A cell-mediated cytotoxic response against human cells 
was elicited in C57BL/6J mice by intraperitoneal injection of 3 ×  10  ? RDMC cells, as previously 
described (26). The cytotoxic test, using effector spleen cells on human adherent target cells, was 
performed as described above, at the peak of the cytotoxic response 11 days after immunization. 
Results 
Additions  of  Exogenous  Interferon  to  Lymphocyte-Target  Cell 
Cultures.  Interferon  preparations  induced  in  human  lymphocytes either  by 
culturing  with  RDMC  monolayers  or  by exposure  to  NDV  were  added  to  a 
mixture  of lymphocytes and  target  RDMC cells in  an  assay of cell-mediated 
cytotoxicity. In the cultures in which interferon was added an enhancement of 
cytotoxicity, usually from two to fourfold, was observed at 4-8 h  of incubation 
(Fig.  1). The rate of cytotoxicity after 8 h  of incubation was usually not higher 
in cultures to which interferon had been added than in control cultures,  high 
levels of endogenous interferon  being present  in both cultures  (Fig.  1).  Some 
cell  lines  were  unable  to  induce  production  of interferon  from  lymphocytes 
(Table  I);  the  use  of these  cells  as  targets  allowed  us  to  detect,  in  some 
experiments, an interferon-induced increase in the rate of cytotoxicity at longer 
incubation  times  also.  However,  the  antagonistic  effect of interferon  on  the 
susceptibility to lysis of most target cells (see below), often reduced the observed 
effect of exogenous interferon preparations on cytotoxicity. 
Effect  of Interferon  Produced  in  the  Lymphocyte-Target  Mixture  on  Cell- 
Mediated Cytotoxicity.  Lymphocytes incubated at 37°C for 24 h completely lose 
their ability to produce interferon when cultured with cells from inducer lines 
(20).  This observation allowed us to evaluate indirectly the effect of interferon 
produced  in  mixed  cultures  on the  spontaneous  cell-mediated  cytotoxicity of 
human  lymphocytes.  Lymphocytes that  were freshly separated  or previously 
incubated 24 h at 37°C were tested as effector cells in an 18-h cytotoxic test (Fig. 
2).  No  difference  was  observed  in  the  cytotoxic  efficiency  of fresh  versus 
preincubated  lymphocytes  when  cells  were  tested  against  targets  unable  to GIORGIO  TRINCHIERI  AND  DANIELA  SANTOLI  1317 
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FIG.  1  Effect  of exogenous interferon on  spontaneous cytotoxicity mbdiated  by human 
lymphocytes  against  RDMC  target  cells.  •  •,  500  anti-viral  U  'of RDMC-induced 
lymphocyte interferon added to  lymphocyte-target cell mixtures at the beginning of the 
cytotoxic test; ©  ©,  no exogenous interferon added during the cytetoxic test; h~  A, 
endogenous  anti-viral  activity  in  the  supernate  of the  cultures  with  no  exogenous  in- 
terferon.  At 4,  8,  and  18 h  of incubation the amounts of 5~Cr release were  significantly 
different (P <  0.01,  Student's t  test) between cultures to which interferon was added and 
those to which it was not  (considering only the dilutions of effector lymphocytes giving 
eytotoxic values in the linear part of the titration curve, 30-70%). 
induce  interferon  (Fig.  2b).  In  contrast,  when  interferon-inducing  cells  were 
targets,  the  cytotoxicity  of the  preincubated  lymphocytes  was  reproducibly 
decreased to only 10-30% of that observed with freshly separated cells (Fig. 2a). 
This observation, reproducible when cell lines other than those in Fig. 2 were 
used as targets, suggests that the interferon released in the culture mediates an 
enhancement  of cytotoxicity that represents up to 70-90% of the total sponta- 
neous cell-mediated  cytotoxicity observed with  fresh lymphocytes in  an  18  h 
test. 
Pretreatment of Lymphocytes  with Interferon.  When  lymphocytes  were 
pretreated for 18 h with interferon preparations then washed and tested as 
effector cells against several  different target  cell lines, they displayed a 
cytotoxic efficiency  up to 10-fold  higher than that of untreated lymphocytes 
(Fig. 3). The increase in the nonspecific cytotoxicity  of human  lymphocytes 
cultured in the presence of  interferon  is  quantitatively comparable to or  higher 
than that observed upon stimulation of lymphocytes with optimal concentra- 
tions  of  phytohaemagglutinin (PHA) (Fig.  3). In some experiments interferon- 
treated cytotoxic lymphocytes induced more than a 50% 5~Cr  release in a 4-h 
test (RDMC  target) at a  ratio of effector  to target of 1:1. These levels  of 
cytotoxicity  were maintained or increased after  lymphocytes were treated for  48 
h with interferon;  beginning on the 3rd day cytotoxicity  declined to levels  close 
to  those of  untreated lymphocytes (Fig.  2).  At 5-7  days in  culture,  a spontaneous 
increase  in the cytotoxicity of the lymphocytes  was usually observed:  the 
presence of  interferon  in the culture depressed this  late  increase (Fig.  2). 
The enhancement  of cytotoxicity  was dependent on the dose of interferon 
added to  the  culture;  a twofold increase was obtained with about 10 anti-viral  U 1318  INTERFERON  AND  HUMAN  NATURAL  KILLER  CELL  ACTIVITY 
TABLE  I 
Human Cell Lines: Ability to Induce Interferon When Cultured with Lymphocytes and 
Susceptibility to the Interferon-Induced Resistance to Cytotoxic Lymphocytes and 
Inhibition of Viral Replication 
Cell line  Origin  Passage 
Units Inter- 
Inhibition  Inhibition 
feron Induced* 
of cytotox-  of viral 
(mean -  Stan- 
dard Error)  icity$  replication§ 
% 
FS1  Fetal skin fibroblasts  14  <1  92  4.0 
Pa  Skin fibroblasts  8  <1  86  3.6 
LR- 1  Newborn brain  4  < 1  82  3.3 
WI38  Fetal lung fibroblasts  42  <1  62  3.0 
MRC5  Fetal lung fibroblasts  45  <1  40  1.8 
LN-SV  Skin, SV40-transformed  253  <1  77  3.0 
W18.VA2  Lung, SV40-transformed  245  <1  75  2.1 
$1054TR  Brain, SV40-transformed  32  193 ±  137  20  <0.3 
SW690  Melanoma  90  850  ±  552  75  2.4 
SW691  Melanoma  85  6,000 ±  3,000  13  <0.3 
SW480  Colorectal carcinoma  112  125 ±  0  24  <0.3 
D98 (HeLa)  Cervical carcinoma  >60  312  ±  165  30  <0.3 
HT1080  Fibrosarcoma  117  0  15  0.6 
RDMC  Rhabdomyosarcoma  203  3,494 ±  1,008  18  <0.3 
*  Anti-viral units in the supernate (24 h incubation of mixed cultures of monolayer of the cell line 
with human lymphocytes; four or more different lymphocyte preparations tested for each cell 
line). 
Average percent inhibition of cytotoxicity. After treatment with interferon (18 h, 103 anti-viral 
U),  cells from the various lines were  tested  as  target  against two different preparations of 
effector lymphocytes (stimulated by 103 anti-viral U of NDV-induced lymphocyte interferon, 18 h). 
§ Loglo of the reciprocal of the dilution of a lymphocyte interferon preparation (NDV-induced, 104 
anti-viral reference U) inhibiting 50% of the cytopathic effect of VSV or monolayer of the cell 
line. 
of interferon administered  for 18 h  (Fig.  4 and 5b). The same enhancement  of 
cytotoxicity was obtained, at equivalent anti-viral doses, with interferon prep- 
arations  obtained  by  stimulation  of human  lymphocytes  with  either  virus 
(NDV) or an  inducer cell line  (RDMC).  When the anti-viral  activity and the 
cytotoxicity-enhancing  activity  of 14  RDMC-induced  interferon  preparations 
from various lymphocyte donors were compared, a  significant positive correla- 
tion  was  observed  (P  <  0.01,  Fig.  5b).  No enhancement  of cytotexicity was 
obtained with supernate from lymphocytes or inducer cell lines cultured alone. 
Supernates from mixed cultures of allogeneic lymphocytes (24 h incubation) and 
from  cultures  of lymphocytes  with  noninducing  cell  lines  neither  displayed 
activity nor enhanced cytotoxicity. 
The cytotoxicity-enhancing activity in the human interferon preparation was 
destroyed by trypsin treatment  (1 mg/ml, 1 h at 37°C, neutralized with soybean 
trypsin inhibitor bound to agarose beads) and was resistant to 5 days treatment 
at pH 2.0.  The cytotoxicity-enhancing activity in the RDMC-induced prepara- 
tions was eluted from a Sephadex G100 column in a peak of approximate mol wt GIORGIO  TRINCHIERI  AND  DANIELA  SANTOLI  1319 
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Fro.  2.  Effect of interferon on the cytotoxic efficiency of human lymphocytes in culture. 
The lymphocytes were cultured for the number of  days indicated in the presence or absence 
of 10  s anti-viral U of RDMC-induced interferon. Their cytotoxic activity was then tested in 
an  18-h  test  against  an  interferon-inducing target,  RDMC  (Fig.  2a),  and  against  a 
noninducing target, FS1 (Fig. 2b).  The relative cytotoxicity is expressed as the ratio of the 
lytic units of the cultured lymphocytes over the lytic units of the freshly separated ones. 
•  •,  no  interferon added;  • .....  E,  interferon added at  time  0;  []  ..... [],  interferon 
added after 24 h of culture at 37°C. 
of 25,000 daltons, corresponding to the major peak of anti-viral activity (Fig. 
6a). Some activity was observed in correspondence with the minor peak of anti- 
viral activity of approximate mol wt 45,000 (20). A variable amount of anti-viral 
activity and concordantly of cytotoxicity-enhancing  activity, were also eluted in 
different experiments with the major peak of protein close to the front of the 
column;  these  results  are  presumably due  to  the  ability  of the  interferon 
molecules to bind to albumin and other proteins (27). 
Medium from lymphocytes stimulated with PHA (HA15, Wellcome Research 
Lab., Beckenham, England, final dilution 1:100, 24 h  incubation at 37°C) con- 
tained some anti-viral (5-50 anti-viral U) and was able to enhance lymphocyte 
cytotoxicity. After gel filtration of the supernate from PHA-stimulated lympho- 
cytes both the anti-viral activity and the cytoxicity-enhancing activity were 
recovered  in  a  peak  discrete  from  the  higher  molecular  weight  activity 
associated with the lectin molecules. 
Mouse interferon preparations obtained from spleen cells and from L cells 
were almost ineffective in enhancing human lymphocyte cytotoxicity. 
Characterization of the Cytotoxic Lymphocytes Affected by Interferon.  The 
cytotoxic lymphocytes showing activity enhanced by interferon were character- 
ized  by  two  techniques:  adherence to  a  nylon fiber  column  and  gradient 
separation of cells rosetted with AET-treated sheep erythrocytes. With these 
separation methods the cytotoxic activities of spontaneous (natural) killer cells, 
antibody-dependent killer cells and the cytotoxic cells with activity enhanced 
by interferon were always associated with the same fractions (Table III).  The 
effector cells responsible for the three activities were non-phagocytic, did not 
adhere to nylon fiber columns, had no detectable surface immunoglobulins, and 1320  INTERFERON  AND  HUMAN  NATURAL  KILLER  CELL  ACTIVITY 
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FIG. 3.  Effect on cell-mediated cytotoxicity of pretreatment of lymphocytes and target 
cells  with interferon preparations. Human  lymphocytes were culture for  18  h at 37°C in the 
presence of  10  s anti-viral  units of  RDMC-induced interferon, PHA  (HAl5 Wellcome, final 
dilution 1/100) or normal RPMI-FBS  medium,  washed three times, and then tested as 
effector  cells  (18-h  test)  on FS1 target cells  pretreated  or not pretreated with 10  ~  anti-viral 
U  of  interferon.  The SD of  each experimental point was less  than 2%. @~@,  untreated 
lymphocytes, untreated target cells;  O .....  O, untreated lymphocytes, interferon-treated 
target cells;  I  ~I, interferon-treated lymphocytes, untreated target cells;  [3  .....  [], in- 
terferon-treated lymphocytes, interferon-treated target cells; •  - 4, PHA-stimulated 
lymphccytes, untreated target cells; A .....  A, PHA-stimulated  lymphocytes, interferon- 
treated cells. 
exhibited very low affinity for sheep erythrocytes (even when the extremely 
sensitive resetting technique with AET-treated sheep erythrocytes was used) 
(28) (Table II). 
When the effect of interferon pretreatment on the antibody-dependent cyto- 
toxic activity of human lymphocytes was tested, no significant increase of the 
antibody-dependent activity was observed in  repeated experiments although 
interferon strongly increased the cytotoxicity of the pretreated lymphocytes 
against the target lymphoid line in the absence of anti-target antibodies (Table 
Ill). 
Inhibition of Target Cell Susceptibility  to Lysis by Pretreatment  with Inter- 
feron,  Incubation of FS1  cells with 103 anti-viral U of RDMC-induced inter- 
feron for 18 h had no toxic effects. The spontaneous release of 5zCr in 18 h was 
27.8 •  2.1 (mean +- SD, six experiments) from untreated target cells and 28.3 
+- 3.3 from pretreated cells: the difference was not significant (Student's test for 
paired data, t --- 0.42, NS). The preincubation of FS1 target cells with interferon 
induced up to 98% protection against the cytotoxicity mediated either by fresh 
or by interferon-stimulated  human lymphocytes (Fig.  3). To reach the maximal 
level of inhibition it was necessary to preincubate the target cells for several GIORGIO  TRINCHIERI  AND  DANIELA  SANTOLI 
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FIG.  4.  Effect  on lymphocytes  and FS1 target cells of pretreatment with different doses of 
interferon. Lymphocytes,  • .....  6, and FS1 target cells, •  I, were incubated for 18 h in 
the presence of the indicated anti-viral units of RDMC-induced interferon and then tested 
reciprocally  against untreated FS1 target cells or against lymphocytes  pretreated with 103 
anti-viral U of interferon. The relative cytotoxicity  is expressed as the ratio between lytic 
units observed  with interferon-pretreated ancl not pretreated lymphocytes  or target cells. 
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hours (Fig. 7). The presence of interferon was not required for the entire period. 
Treating of FS1 cells for 30 min with interferon, then incubating them for 24 h 
without interferon induced an 85% inhibition of cytotoxicity, whereas pretreat- 
ment for 30 rain immediately before the test induced only 35% inhibition (Fig. 
7). The induction of resistance to lysis upon pretreatment with interferon (Fig. 
8a)  was prevented by concurrent treatment of FS1  cells with an  inhibitor of 
RNA synthesis (actinomycin D, Fig. 8b) or with an inhibitor of  protein synthesis 
(cycloheximide, Fig.  8c).  Virus  infection of the target cells  (influenza A  and 
vaccinia viruses) also prevented the induction of most of the resistance in FS1 
cells (Fig. 8d and e). 
14 different cell lines have been tested for interferon-mediated induction of 
resistance  to  the  cytotoxic effect of lymphocytes  (Table  I).  Fibroblasts  are 
susceptible to both the anti-viral and target protective activities of interferon. 
The fetal lung fibroblasts WI38 and MRC5,  tested in the experiment shown in 
Table I, were at very high passage and were relatively less susceptible to both 
interferon activities; other experiments with lower passages of these same cells 
showed  a  higher  susceptibility  to  the  two  activities.  When  various  SV40- 
transfomed or tumor-derived cell lines were tested, a  variable susceptibility to 
interferon  was  observed  in  different  lines.  The  tumor-derived  lines  tested, 
however, were not susceptible to either the anti-viral or the target protective 
activity of interferon, with the exception of the melanoma-derived SW690 cell 
line. A significant positive correlation was observed between cell line suscepti- 
bility to the anti-viral and to the target protective activity of interferon (r  = 
0.954, P  <  0.001). 1322  INTERFERON  AND  HUMAN  NATURAL  KILLER  CELL  ACTIVITY 
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Fro.  5.  Correlation between anti-viral activity and (a) protective effect on target cells or 
(b) enhancing activity  on cytotoxic  lymphocytes in  15  different preparations of RDMC- 
induced interferon.  The different preparations were titrated for inhibition of target cell 
(FS1) susceptibility to lysis and enhancement of lymphocyte cytotexicity as shown in Fig. 
4.  Target inhibitory units are defined as the reciprocal of the titer inhibiting 50% of the 
cytotoxicity on FS1 target cells mediated by lymphocytes stimulated with 108 anti-viral U 
of interferon (data shown are the average of two determinations with lymphocyte prepara- 
tions from different donors).  Effector-enhancing units are defined as the reciprocal of the 
titer  inducing a  twofold  increase  in the  cytotoxicity  of pretreated  lymphocytes  on  FS1 
target cells.  Correlation between  anti-viral activity  and target  inhibitory activity: r  = 
0.945, P  <  0.001; correlation between anti-viral activity and effector enhancing activity: r 
=  0.628, P  <  0.01. 
The  interferon-mediated  inhibition  of target  cell susceptibility to lysis was 
dose dependent:  1-2 anti-viral U  of interferon were required for 50% inhibition 
of cytotoxicity on FS1 target cells (Fig. 4 and 5a). Inhibition of cytotoxicity was 
observed with both NDV- and RDMC-induced lymphocyte interferon.  The anti- 
viral activity and the target protective activity were tested in 15 RDMC-induced 
interferon  preparations  obtained  with  lymphocytes  from  different  donors:  a 
significant  positive correlation  was observed between the two activities  (r  = 
0.945, P  <  0.001; Fig. 5a). None of the control preparations described for effector- 
enhancing  activity contained  anti-viral  activity,  and  neither  they nor mouse 
interferon  preparations  were able to induce resistance  in human target cells. GIORGIO  TRINCHIERI  AND  DANIELA  SANTOLI 
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FIG. 6.  Gel filtration on Sephadex G100 fine column of (a) RDMC-induced and (b) NDV- 
induced interferon preparations. 30 ml of preparation was concentrated ten times to 3 ml by 
vacuum dialysis.  Column bed 25  x  960 mm (471 cmS), void vol 160 ml. Arrows indicate 
molecular  weight  markers,  from left  to right: blue  dextran  2,000 (mol  wt  2,000,000), 
aldolase  (158,000), ovalbumin  (45,000),  chymotrypsinogen  A  (25,000),  ribonuclease  A 
(13,700). The collected fractions were dialyzed against medium, sterilized by filtration, and 
tested  for anti-viral activity,  enhancing activity  on cytotoxic lymphocytes (RDMC target 
cells,  8-h test, cytotoxicity of untreated lymphocytes: 1.04 lytic U/106 cells) and inhibitory 
activity on FS1 target cells (18-h pretreatment,  18-h test, effector lymphocytes stimulated 
with 10  a anti-viral units of interferon). 
TABLE II 
Effect of Interferon on Lymphocyte Subpopulations 
1323 
Fraction  ANAE*  S-Ig*  E-RFC§  Ab-CMC[[  Sp-CMC¶  If-CMC** 
If-CMC 
Sp-CMC 
Exp. A 
Ficoll-Hypaque  separated  cells  17.9  22.7  62.9  250  555  1,224  2.2 
Nylon column nonadherant  1.4  2.4  86.4  909  1,111  3,571  3.2 
Nylon column adherent  30.4  55.8  24.2  95  83  250  3.0 
Exp. B 
Nylon column non-adharent  0.9  1.7  88.4  192  313  714  2.3 
AET-SRBC  Non-resetting  11.4  32.0  0  326  1,562  4,348  2.8 
AET-SRBC  Rceetting  0  0  97.6  50  59  153  2.6 
* Staining for nonspecific  acid estersee (20), strongly  positive  cells (monocytee). 
* Positive  fluorescence  for surface immunoglobulin  with fluoresrein-tagged  rabbit F(ab')1 anti-human  light chains. 
§ Cells forming ro~ttes with AET-treated  sheep erythrocytes  (18 h incubation  at 4°C) (22). 
II Lytic U/10  s cells in antibody-dependent  cell-mediated  cytotoxicity. 
¶ Lytic U/10* cells, 9 h test, RDMC target cells, effector cells preincubated  18 h in RPMI-FBS. 
** Lytic U/10* cells, 8 h test, RDMC target cells, effector cells preincubated  18 h with 500 anti-viral  U of RDMC-inducod  interferon. 
The protective activity was resistant to pH 2.0 and destroyed by treatment with 
trypsin.  Gel filtration  on a  Sephadex G100 column of NDV-induced  interferon 
gave  a  peak of anti-viral  and target  protective  activity  with  an  approximate 
mol wt of 25,000 daltons; in addition,  as discussed above, a  variable proportion 
of the activity was eluted with the major protein peak (Fig.  6b). 
Characteristics  of Interferon-Mediated  Target  Cell  Resistance  to  Cytotoxic 
Lymphocytes.  FS1 target cells treated with 103 anti-viral U  of interferon for 18 
h  were  almost  completely  resistant  to  the  cytotoxic  effect  of  spontaneous 1324  INTERFERON  AND  HUMAN  NATURAL  KILLER  CELL  ACTIVITY 
TABLE  III 
Effect of Interferon on Antibody-Dependent Cell-Mediated  Cytotoxicity 
Time in  culture  Interferon  EB-P8 Tar-  Increase*  EB-P8 Target +  Increase* 
get*  Anti-HLA* 
h 
0  0  30  2,564 
24  0  28  3.3  1,056 
24  500  93  1,250 
48  0  24  952 
12.6  48  500  303  1,250 
1.18 
1.31 
Lymphocytes were cultured in presence or absence of 500 anti-viral  units  of RDMC-induced 
interferon  and tested  at the different  times in a 4-h assay against EB-P8 cells  sensitized  or not 
sensitized  with a mixture of  appropriate anti-HLA sera. 
* Lyric U/108 cells. 
$ Ratio between lytic  units  of  lymphocytes incubated in  the presence and absence of  interferon. 
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Fro.  7.  Induction of target cell (FS1) resistance to lysis after pretreatment with interferon 
for different time periods. FS1 target cells were pretreated with 108 anti-viral U of RDMC- 
induced  interferon  for  the  times  indicated,  washed  three  times,  and  tested  against 
interferon-stimulated  (103 anti-viral  U,  18-h  pretreatment)  cytotoxic  lymphocytes.  The 
solid dot indicates the cytotoxic effect on FS1 cells incubated for 30 rain in the presence of 
interferon, washed and incubated without interferon for 24 h  before testing. The relative 
cytotoxicity  is  expressed  as  the  ratio  between  lytic  units  obtained  against  interferon- 
pretreated and untreated target cells. 
(natural)  cytotoxic  lymphocytes  and  interferon-stimulated  lymphocytes,  but 
were  only partially  protected  against  PHA-induced  cytotoxic  human lympho- 
cytes  (Fig.  3).  Moreover,  in  repeated  experiments  treated  and untreated  FS1 
cells were equally susceptible to mouse anti-human cytotoxic T cells. 
Interferon-treated  and  untreated  unlabeled  FS1  cells  (cold  targets)  were 
tested for their ability to compete for the killing of [51Cr]labeled FS1 cells, using 
interferon-stimulated  human lymphocytes as effector cells.  5  ×  104 cold target 
cells treated or not treated with interferon were added to the wells of microtiter GIORGIO  TRINCHIERI  AND  DANIELA  SANTOLI 
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FIG.  8.  Effects of metabolic inhibitors or virus infection on interferon-mediated inhibition 
of target cell (FS1) susceptibility to lysis.  •  •,  FS1 cells not treated with interferon; 
©  ©, FS1 cells treated with interferon,  a: FS1 cells were pretreated  for 18 h  with 10  s 
anti-viral  U  of RDMC-induced  interferon  and  then  tested  against  different dilutions of 
interferon-stimulated (10  a anti-viral units, 18 h pretreatment) cytotexic lymphocytes, b,c: 1 
h  before and  during  interferon treatment  1  /~g/ml of aetinomycin  D  (b)  or 50  ~g/ml of 
cycloheximide (c) were added,  d,e: 1 h before interferon treatment FS1 cells were infected 
with 0.1  ml (850  HAU/ml) of the HK strain  of influenza A  virus (d) or with 0.1  ml (10  e 
TCID50/ml) of the Lister strain of vaccinia virus (e).  The SD of each experimental point 
was less than 2%. 
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FIG.  9.  Cold target competition experiment with interferon-treated or untreated compet- 
itor cells. 5  x  104 treated (10  ~ anti-viral U, 18 h) or untreated FS1 cells were added to 2  x 
104 adherent [~lCr]labeled FS1 target cells. Effecter cells were interferon-stimulated human 
lymphocytes; the incubation time of the cytotoxic test was 11 h. The SD of each experimen- 
tal point was less than 2%.  @-----@, no cold target cells; A ..... A, interferon-treated FS1 
cold target cells; •  A, untreated FS1 cold target cells. 
plates  containing  a  monolayer  of about  2  ×  10  4 target  cells  labeled  with  51Cr. 
Different  dilutions  of effector lymphocytes  were  then  added:  as depicted  in Fig. 
9  about  75%  inhibition  of cytotoxicity  was  observed  with  untreated  cold target 
cells,  whereas  no inhibition  was  obtained  with  interferon-treated  cells. 1326  INTERFERON  AND  HUMAN  NATURAL  KILLER  CELL  ACTIVITY 
Discussion 
Since its disovery in 1957 by Isaacs and Lindenmann (29) as "an anti-viral 
substance produced by cells in response to virus infection", interferon has been 
shown to  affect various cellular functions not directly connected with viral 
replication and to be induced by a variety of non-viral stimuli. In vivo interferon 
may regulate several cellular functions and defense mechanisms, and its anti- 
viral activity may represent only one aspect of its physiological role. Interferon 
is induced in immunological reactions, and it may either stimulate or depress 
several immune functions (1-9). 
Interferon  probably  enhances  a  specific  cell-mediated cytotoxic  response 
against tumor antigens, in analogy to what has been demonstrated for alloreac- 
tive response (5, 6), and also stimulates nonspecific defense mechanisms such as 
phagocytosis (7, 8) and nonspecific cell-mediated cytotoxicity (9). Stimulation of 
the host defense mechanisms to more efficiently oppose tumor growth, and a 
direct effect on tumor cell  DNA  synthesis and replication,  which decreases 
tumor growth rate  and  invasiveness,  are probably responsible for the  anti- 
tumor  effect in  vivo  of interferon  and  interferon  inducers  (30). We  have 
demonstrated that most tumor-derived cell cultures have the ability to induce 
human  and  mouse  lymphocytes to  produce  interferon  in  vitro  (20). This 
observation suggests that in vivo transplantable tumors used in experimental 
tumor immunology, and possibly spontaneous tumors, induce interferon, which, 
in the first phases of tumor growth, might stimulate host defense mechanisms. 
The present study demonstrates that induction of lymphocyte interferon by 
tumor-derived cells affects the natural cytotoxic activity of human lymphocytes 
present  in  the  cultures.  Interferon  preparations  increase  several  fold  the 
nonspecific cytotoxicity of human lymphocytes: the effector cells are cytotoxic 
for any target cell line tested, regardless of the cell line (or virus) used to induce 
interferon. Cell separation experiments showed that the activity of spontaneous 
(natural) killer lymphocytes could not be separated from the cytotoxic activity 
induced by interferon preparations. This observation suggests that interferon 
preparations do not  generate a  new population of effector cells,  but  rather 
enhance the activity of the natural killer cells or increase their number by 
recruiting quiescent cells.  All  the  evidence indicates that  in  the  interferon 
preparations it is the interferon itself that mediates the cytotoxicity-enhancing 
activity (31, 32). A very good correlation was found in beth tumor cell-induced 
and virus-induced interferon preparations between anti-viral and cytotoxicity- 
enhancing activities. All control preparations were negative for both activities; 
moreover, the cytotoxicity-enhancing activity showed the  species preference 
and the physicochemical characteristics of interferon. 
The mechanism by which interferon enhances lymphocyte  cytotoxicity is still 
obscure. Interferon does not act directly on target cells: interferon preparations 
are not toxic for target cells and the enhancement of cytotoxicity is present 
when lymphocytes are  pretreated with  interferon and  washed before being 
tested as effector cells. The effect of interferon on cytotoxic lymphocytes is not 
immediate, but reaches a maximum after several hours; addition of interferon 
to a  lymphocyte target cell mixture is less efficient than pretreating lympho- 
cytes with interferon. Interferon therefore does not act by providing a recogni- GIORGIO  TRINCHIERI  AND  DANIELA  SANTOLI  1327 
tion-binding system, as, for example, IgG molecules do in inducing antibody- 
dependent cell-mediated cytotoxicity, but directly stimulates effecter cells. It is 
not  possible  to  determine whether this  stimulation  requires  active protein 
synthesis in cells, because although protein synthesis in the lymphocytes is not 
required for immediate cytotoxicity, pretreatment of lymphocytes with protein 
synthesis inhibitors determines a  decrease of the cytotoxic efficiency (33 and 
our unpublished observation). This observation however suggests that cytotoxic 
activity of lymphocytes requires protein factors with a  rapid turnover; inter- 
feron, which has been shown, for example, to increase the expression of H-2 
antigens on murine cells (34), might affect the synthesis of such factors. 
It  has  been  suggested  that  human  natural  killer  cell  activity  is  partly 
mediated by IgG antibodies adsorbed to the Fc-receptor of antibody-dependent 
cytotoxic lymphocytes (19); in this case two mechanisms that might increase 
cytotoxicity would be an enhancement of the efficiency of antibody-dependent 
killer cells or an induction of in vitro synthesis of IgG able to arm killer cells. 
Both of these mechanisms seem to be excluded by the following observations (a) 
the activity of antibody-dependent killer cells is not enhanced by interferon 
(Table III); (b) interferon inhibits antibody secretion in several in vitro systems 
(4); (c) the cytotoxicity and the generation of interferon-induced killer cells is 
not affected by concentrations of rabbit f(ab')2 fragment anti-human IgG able to 
completely suppress  antibody-dependent cell-mediated cytotexicity  (25  and 
our unpublished observation). 
The interferon-mediated enhancement of cytotoxicity in vitro lasted for 2-3 
days. After 6-8 days of incubation the cytotoxicity  of  the untreated lymphocytes, 
which reached its lowest level at 4-5 days, increased again to levels close to or 
higher than those observed with freshly separated lymphocytes. This nonspe- 
cific  increase  of  cytotoxicity,  which  parallels  a  simultaneous  increase  in 
[3H]thymidine incorporation in  the lymphocytes, is  depressed by interferon. 
This phenomenon might be due to a  polyclonal T-cell stimulation induced by 
mitogenic factors present in the culture medium or serum, however the nature 
of the effector cells involved has not been analyzed. 
Various  phenomena  have  been  described  which  may  be  related  to  the 
cytotoxicity-enhancing  activity of interferon. Peter et al.  (35) reported that in 
mixed cultures of human lymphocytes and tumor-derived cell lines, a factor is 
released  that  inhibits  DNA  synthesis  and  enhances  the  spontaneous  cell- 
mediated cytotoxicity of lymphocytes. That factor could be identical to the cell- 
induced lymphocyte interferon that we have described. Although Peter et al. 
considered the factor a  lymphotoxin, no evidence of a  direct toxic effect was 
presented.  Several studies  have  shown that  human lymphocytes kill  virus- 
infected cells more efficiently than uninfected target cells  (36-41): although 
anti-viral antibodies adsorbed on the membranes of the lymphocytes  or secreted 
in the culture play a role in some systems (40, 41), lymphocytes cultured with 
virus-infected cells,  or directly with virus,  produce high level of interferon, 
which is the main factor responsible for the observed increase in cytotoxicity.  2 It 
2 D.  Santoli, G. Trinchieri, and H.  Koprowski.  Cell-mediated cytotoxicity in humans against 
virus-infected target cells. II. Interferon induction and activation of natural  killer cells. Manu. 
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has been reported that cytotoxic effector cells are generated by culturing human 
lymphocytes with tumor-derived cell lines (42-44). Although no direct analysis 
has been reported in these studies, we assume that in some of these systems the 
effector cells are probably induced by interferon released in the culture system. 
Porzsolt et al.  (44) have described the generation  of cytotexic cells in a  mixed 
culture  of human  lymphocytes  and  cultured  melanoma  cells  with  kinetics 
resembling that obtained with interferon stimulation  (Fig. 2). Rapid induction 
of human cytotexic lymphocytes in vitro has also been described with interferon 
inducers,  such  as  synthetic  polyribonucleotides  (45)  and  Bacillus  Calmette- 
Guerin  (BCG)  (46),  and  variously  interpreted.  In  vivo  it  has  been  reported 
that  injection  of viruses  (47) or BCG (47,  48)  into mice increases the natural 
killer cell activity with a  peak at day 3.  Interestingly,  the same phenomenon 
has been described after injection of transplantable  tumor cell lines (47); some 
of these same cell lines have been tested in our laboratory and found to be able 
to induce interferon in vitro when cultured with human or mouse lymphocytes 
(2O). 
When target cells are treated with interferon, they are less susceptible to the 
cytotoxicity of effector lymphocytes.  Interferon-treated  fibroblasts  are  almost 
completely resistant to nonspecific cytotoxic lymphocytes. The refractory status 
of the target cells appears specific for the cytotoxicity mediated by natural killer 
cells; the  spontaneous  or interferon-enhanced  cytotexicity of human  lympho- 
cytes is almost completely suppressed, whereas the activity of mouse cytotoxic 
T cells is not affected. Human cytotoxic lymphocytes induced with PHA, which 
probably stimulated both cytotoxic T cells and natural killer cells (49), are only 
partially inhibited.  Interferon therefore does not induce a general resistance in 
target cells: the inability of interferon-treated cold target cells to competitively 
inhibit the cytotoxicity of natural killer cells suggests that in the treated cells 
some  surface characteristics  responsible for recognition  by cytotoxic lympho- 
cytes are lost or masked. Although the phenomenon of the specific inhibition of 
the  target  cells cannot yet be interpreted,  we feel that  this  observation may 
provide a  clue for the specificity of the natural killer cells. Two considerations 
suggest  that  interferon  does not  act  by affecting  the  expression  of antigens 
coded by endogenous viruses present in the target cells and recognized by the 
cytotoxic cells  (50): no evidence of the  presence  of virus or viral  antigens  in 
normal  human  fibroblasts  have  ever been  obtained  and  interferon  increases 
rather  than  decreases the expression of C-type virus antigens  or particles on 
the surface of murine cells (51). 
The identification of the molecules mediating the protection of target cells as 
interferon  is  based  on  the  same  characteristics  already  mentioned  for  the 
cytotoxicity-enhancing effect. Further, these traits meet the criteria established 
by  Lockart  (31)  and  Oxman  (32)  for  the  identification  of  interferon.  The 
protection of target  cells by interferon  is not direct.  Rather,  the experiments 
with metabolic inhibitors  suggest that interferon  acts  through an intraceUular 
mechanism  that involves synthesis by the cells  of both RNA  and protein. 
Infection  with influenza A or vaccinia virus decreased or, in  some experiments, 
abolished the induction of  resistance to lysis  in the target cells;  this  phenome- 
non, which has also  been observed for  the antiviral  activity  of  interferon,  may GIORGIO  TRINCHIERI  AND  DANIELA  SANTOLI  1329 
be due to the inhibition of host cell protein synthesis after infection with the 
two viruses tested (52,  53). The ability of different cell lines to respond to the 
anti-viral  and  to  the  target  inhibitory  activities  of interferon were  strictly 
correlated.  Because  cell  susceptibility  to  other  effects  of  interferon  (e.g., 
inhibition of DNA synthesis and of cell growth) is not correlated with suscepti- 
bility to anti-viral activity, this correlation might indicate that the anti-viral 
and the target inhibitory effects of interferon follow a  common intracellular 
pathway. Experiments with human-mouse somatic cell hybrids are in progress 
to test if products of the human chromosome 21, which presumably codes for the 
anti-viral  protein  (54),  are  responsible  for  the  target  inhibitory  activity  of 
interferon. 
The protective effect of interferon on target cells offers a possible explanation 
of the paradoxical existence in vivo of natural killer cells, which, in Vitro, can 
efficiently lyse any target cells, including normal autologous cells (13). Normal 
fibroblasts  are more susceptible,  in general, to the anti-viral  and target cell 
inhibitory activities of interferon than cultured tumor cells or virus-infected 
cells. Interferon, by stimulating very efficient nonspecific cytotoxic cells and by 
simultaneously protecting normal cells from lysis,  might render the natural 
killer cell system an inducible selective defense mechanism against tumor cells 
or virus-infected cells.  Some tumor cell lines however (for example SW690  in 
Table  I)  maintained  their  susceptibility  to  the  interferon  target  inhibitory 
activity: in this case interferon, by protecting the cells from lysis, may furnish 
an efficient escape mechanism to the tumor. A phenomenon of this type may 
perhaps  explain why, in some transplantable  tumor systems in mice, tumor 
cells cultured in vitro are more susceptible to killer cells than those grown in 
vivo (55, 56). 
It is, however, difficult to speculate about the actual role that interferon has 
in vivo in regulating nonspecific defense mechanisms either in physiological 
conditions or during growth of spontaneous tumor and during viral infection. 
Mouse spleen cells from apparently healthy animals and, in some cases, human 
peripheral blood lymphocytes, spontaneously secrete low levels of interferon, 
suggesting that the presence of subliminal amounts of interferon are present in 
vivo  even in  physiological conditions.  It  is  possible  that  the  activity of the 
natural killer cells present in vivo is maintained by a  continuous stimulation 
mediated by this low level of interferon. A better understanding of the role of 
interferon in vivo in modulating natural killer cell activity in physiological, 
pathological or experimental conditions must await further investigation. 
Summary 
Interferon, induced in lymphocytes either with viruses or cell lines, increases 
severalfold the natural cytotoxicity of human lymphocytes on target cell lines. 
Cell separation experiments support the hypothesis that interferon enhances 
the activity of natural killer cells rather than generating a  new population of 
effeetor cells. In mixed culture of lymphocytes and cell lines in which endoge- 
nous interferon is produced, interferon mediates an enhancement of cytotoxicity 
that represents up to 70-90% of  the observed eytotoxicity. The effect of interferon 
on target cells is antagonistic to the effect on the lymphocytes: the susceptibility 1330  INTERFERON  AND  HUMAN  NATURAL  KILLER  CELL  ACTIVITY 
to  cell-mediated  lysis  of various  cells  upon  pretreatment  with  interferon  is 
decreased and in some cases almost completely suppressed.  Interferon renders 
target cells resistant to natural killer cells acting by an intracellular mechanism 
which  requires  RNA  and  protein  synthesis.  While  normal  fibroblasts  are 
protected, virus-infected cells and most tumor cells usually are not protected by 
interferon.  Interferon by stimulating  very efficient nonspecific cytotoxic cells 
and by protecting at the same time normal cells from lysis, might render the 
natural  killer  cell  system  an  inducible  selective defense mechanism  against 
tumor and virus-infected cells. 
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